Talphera (NASDAQ:TLPH) Stock Price Crosses Below 200-Day Moving Average – Here’s What Happened

Talphera, Inc. (NASDAQ:TLPH)’s share price passed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $1.01 and traded as low as $0.77. Talphera shares last traded at $0.9060, with a volume of 1,219,659 shares changing hands.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on TLPH shares. HC Wainwright reiterated a “buy” rating and set a $3.00 price target on shares of Talphera in a research report on Thursday, August 13th. Wall Street Zen raised Talphera to a “hold” rating in a report on Saturday, August 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Talphera in a report on Thursday, October 15th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $3.00.

Talphera Trading Down 12.5%

The company has a market cap of $47.03 million, a price-to-earnings ratio of -4.31 and a beta of 0.77. The business has a 50-day moving average price of $1.11 and a 200 day moving average price of $1.01.

Talphera (NASDAQ:TLPH) last issued its earnings results on Thursday, November 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.05). On average, analysts anticipate that Talphera, Inc. will post -0.23 earnings per share for the current year.

About Talphera

Talphera, Inc., formerly known as AcelRx Pharmaceuticals, is a specialty pharmaceutical company focused on developing and commercializing treatments for acute pain and critical care. The company’s portfolio includes DSUVIA, a sublingual formulation of sufentanil for the management of acute pain in adults in medically supervised settings. Talphera is also developing Niyad, a nafamostat-based anticoagulant intended for use in extracorporeal circuits during continuous renal replacement therapy. The company’s work in this area is aimed at addressing treatment needs in critical care settings.